Save up -80% on Suvorexant
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Belsomra
|$354.20||30 tablets/20 mg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Belsomra coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Suvorexant every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Suvorexant volume of distribution
The mean volume of distribution of suvorexant is approximately 49 liters. Suvorexant is extensively bound (>99%) to human plasma proteins and does not preferentially distribute into red blood cells.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Suvorexant
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Suvorexant mechanism of action
Suvorexant is a dual antagonist of orexin receptors OX1R and OX2R. It exerts its pharmacological effect by inhibiting binding of neuropeptides orexin A and B, also known as hypocretin 1 and 2, that are produced by neurons in the lateral hypothalamus. These neurons control the wake-promoting centers of the brain and are active during wakefulness, especially during motor activities, and stop firing during sleep. By inhibiting the reinforcement of arousal systems, suvorexant use causes a decrease in arousal and wakefulness, rather than having a direct sleep-promoting effect.
Dosage forms of Suvorexant
Merck Sharp – Dohme Corp.
Indication of Suvorexant
Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Toxicity of Suvorexant
Dose-related somnolence and CNS depression are the most common adverse effects associated with the use of suvorexant. It has also been shown to impair driving skills and may increase the risk of falling asleep while driving. Next-day impairments are found to be highest if suvorexant is taken with less than a full night of sleep remaining, with higher doses, or if co-administered with other CNS depressants or CYP3A inhibitors. Complex behaviours such as sleep driving, preparing and eating food, and making phone calls have been reported in association with the use of hypnotics such as suvorexant. A dose-dependant increase in suicidal ideation has been observed, especially in patients with a previous diagnosis of depression. Sleep paralysis, hypnagogic/hypnopompic hallucinations including vivid and disturbing perceptions, and mild cataplexy have also been reported. There are no adequate studies in pregnant women to ensure its safety during pregnancy or breast feeding.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Suvorexant on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.
Get lower price on Suvorexant now!
What is Belsomra?
Belsomra is a sleeping pill of a new generation, the only drug that does not cause sleep, but “blocks wakefulness.” In contrast to previously known hypnotic drugs, Belsomra has practically no contraindications (except for the rare disease narcolepsy) and side effects. The drug has been developed by pharmacists relatively recently, but has already been recognized by doctors as an effective and safe means. With suvoreksant you can gain a healthy and high-quality sleep, without suffering later daytime sleepiness or headaches.
The drug Belsomra developed on the basis of modern research in the field of sleep. The principle of operation of suvorexant is the effect on orexin receptors: a protein neurotransmitter that ensures the process of wakefulness. OX1 and OX2 are orexin receptors, the blocking of which ensures the rapid onset and maintenance of all phases of sleep without exerting a retarding effect on the central nervous system.
Thus, the mechanism of action of the drug suvorexant provides for blocking wakefulness, which significantly distinguishes it from all the drugs already on the market to combat sleep disorders that provoke the onset of sleep. Acceptance of suvorexant in the minimum dose allows not only to improve the quality of sleep, but also to increase the rate of its onset by 40%.
Most of the hypnotic drugs cause pronounced muscle relaxation, which is the reason for the cessation of breathing in sleep and is unacceptable for patients with neurological, endocrine, and pulmonary diseases. The peculiarities of the preparation Belsomra, which allow it not to exert a depressant effect on the respiratory center, make it possible to apply this soporific in patients suffering from obstructive sleep apnea and chronic nocturnal hypoxemia.